Literature DB >> 34863359

The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.

Tom H Karlsen1, Nick Sheron2, Shira Zelber-Sagi3, Patrizia Carrieri4, Geoffrey Dusheiko5, Elisabetta Bugianesi6, Rachel Pryke7, Sharon J Hutchinson8, Bruno Sangro9, Natasha K Martin10, Michele Cecchini11, Mae Ashworth Dirac12, Annalisa Belloni13, Miquel Serra-Burriel14, Cyriel Y Ponsioen15, Brittney Sheena16, Alienor Lerouge11, Marion Devaux11, Nick Scott17, Margaret Hellard18, Henkjan J Verkade19, Ekkehard Sturm20, Giulio Marchesini21, Hannele Yki-Järvinen22, Chris D Byrne23, Giovanni Targher24, Aviad Tur-Sinai25, Damon Barrett26, Michael Ninburg27, Tatjana Reic28, Alison Taylor29, Tim Rhodes30, Carla Treloar31, Claus Petersen32, Christoph Schramm33, Robert Flisiak34, Marieta Y Simonova35, Albert Pares36, Philip Johnson37, Alessandro Cucchetti38, Isabel Graupera39, Christos Lionis40, Elisa Pose41, Núria Fabrellas42, Ann T Ma43, Juan M Mendive44, Vincenzo Mazzaferro45, Harry Rutter46, Helena Cortez-Pinto47, Deirdre Kelly48, Robyn Burton49, Jeffrey V Lazarus50, Pere Ginès39, Maria Buti51, Philip N Newsome52, Patrizia Burra53, Michael P Manns54.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 34863359     DOI: 10.1016/S0140-6736(21)01701-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  24 in total

1.  Long-term outcomes in patients with non-alcoholic fatty liver disease: further evidence that a multidisciplinary and patient-centred approach to treatment is needed.

Authors:  Giovanni Targher
Journal:  Hepatobiliary Surg Nutr       Date:  2022-02       Impact factor: 7.293

2.  Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.

Authors:  Thomas Marjot; Christiane S Eberhardt; Tobias Boettler; Luca S Belli; Marina Berenguer; Maria Buti; Rajiv Jalan; Mario U Mondelli; Richard Moreau; Daniel Shouval; Thomas Berg; Markus Cornberg
Journal:  J Hepatol       Date:  2022-07-20       Impact factor: 30.083

Review 3.  Identification of liver disease: why and how.

Authors:  Iain Macpherson; Kushala W M Abeysekera; Rebecca Harris; Dina Mansour; Stuart McPherson; Ian Rowe; William Rosenberg; John F Dillon; Andrew Yeoman
Journal:  Frontline Gastroenterol       Date:  2022-01-24

Review 4.  Understanding the cellular interactome of non-alcoholic fatty liver disease.

Authors:  Sebastian J Wallace; Frank Tacke; Robert F Schwabe; Neil C Henderson
Journal:  JHEP Rep       Date:  2022-06-15

5.  Noninvasive proteomic biomarkers for alcohol-related liver disease.

Authors:  Lili Niu; Maja Thiele; Philipp E Geyer; Ditlev Nytoft Rasmussen; Henry Emanuel Webel; Alberto Santos; Rajat Gupta; Florian Meier; Maximilian Strauss; Maria Kjaergaard; Katrine Lindvig; Suganya Jacobsen; Simon Rasmussen; Torben Hansen; Aleksander Krag; Matthias Mann
Journal:  Nat Med       Date:  2022-06-02       Impact factor: 87.241

6.  LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries.

Authors:  Isabel Graupera; Maja Thiele; Ann T Ma; Miquel Serra-Burriel; Judit Pich; Núria Fabrellas; Llorenç Caballeria; Robert J de Knegt; Ivica Grgurevic; Mathias Reichert; Dominique Roulot; Jörn M Schattenberg; Juan M Pericas; Paolo Angeli; Emmanuel A Tsochatzis; Indra Neil Guha; Montserrat Garcia-Retortillo; Rosa M Morillas; Rosario Hernández; Jordi Hoyo; Matilde Fuentes; Anita Madir; Adrià Juanola; Anna Soria; Marta Juan; Marta Carol; Alba Diaz; Sönke Detlefsen; Pere Toran; Céline Fournier; Anne Llorca; Phillip N Newsome; Michael Manns; Harry J de Koning; Feliu Serra-Burriel; Fernando Cucchietti; Anita Arslanow; Marko Korenjak; Laurens van Kleef; Josep Lluis Falcó; Patrick S Kamath; Tom H Karlsen; Laurent Castera; Frank Lammert; Aleksander Krag; Pere Ginès
Journal:  BMC Public Health       Date:  2022-07-19       Impact factor: 4.135

7.  Evaluation of a novel therapeutic education programme for people with alcohol use disorder in France: a mixed-methods intervention study protocol (ETHER).

Authors:  Saskia Antwerpes; Marie Costa; Marion Coste; Morgane Bureau; Gwenaelle Maradan; Christophe Cutarella; Jacques Leloutre; Olivier Riccobono-Soulier; Sophie Hedoire; Elodie Frot; Fabienne Vernier; Stéphanie Vassas-Goyard; Tangui Barré; Danielle Casanova; Patrizia Carrieri
Journal:  Harm Reduct J       Date:  2022-01-10

8.  Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life.

Authors:  Marta Carol; Martina Pérez-Guasch; Elsa Solà; Marta Cervera; Sara Martínez; Adrià Juanola; Ann T Ma; Emma Avitabile; Laura Napoleone; Elisa Pose; Isabel Graupera; Maria Honrubia; Marko Korenjak; Ferran Torres; Pere Ginès; Núria Fabrellas
Journal:  PLoS One       Date:  2022-04-06       Impact factor: 3.240

9.  Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?

Authors:  Paweł Pabjan; Michał Brzdęk; Magdalena Chrapek; Kacper Dziedzic; Krystyna Dobrowolska; Katarzyna Paluch; Anna Garbat; Piotr Błoniarczyk; Katarzyna Reczko; Piotr Stępień; Dorota Zarębska-Michaluk
Journal:  Viruses       Date:  2022-01-06       Impact factor: 5.048

10.  Pathophysiology of Chronic Liver Disease Development.

Authors:  Malin Fromme; Pavel Strnad
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.